{"DataElement":{"publicId":"3233415","version":"1","preferredName":"Patient Progressive Disease Clinical Trial Eligibility Criteria Ind-2","preferredDefinition":"the yes/no indicator related a disease process that is increasing in scope or severity as an element of the personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"3233413v1.0:2018257v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3233413","version":"1","preferredName":"Patient Progressive Disease Clinical Trial Eligibility Criteria","preferredDefinition":"information related a disease process that is increasing in scope or severity as an element of the personal medical history which is necessary to allow an individual to participate in a specific clinical trial.","longName":"2177068v1.0:3233411v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177068","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"Patient","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7AB6-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3233411","version":"1","preferredName":"PD Clinical Trial Eligibility Criteria","preferredDefinition":"Cancer that is increasing in scope or severity.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C35571:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A275CA77-4754-E2C8-E040-BB89AD434F94","latestVersionIndicator":"Yes","beginDate":"2011-05-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-04","modifiedBy":"ONEDATA","dateModified":"2011-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A275CA77-4765-E2C8-E040-BB89AD434F94","latestVersionIndicator":"Yes","beginDate":"2011-05-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-04","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"},{"name":"PT_RP_CHX_ELIG_IND","type":"COG GDE Short Name","context":"COG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"Progressive disease with any","type":"Preferred Question Text","description":"Progressive disease with any one of the following characteristics based on standard criteria for treatment as defined by the NCI-WG 1996 (Cheson, 1996 and Hallek, 2008).  1. Symptomatic CLL characterized by any one of the following:   a. Weight loss >=10% within the previous 6 months   b. Extreme fatigue attributed to CLL   c. Fevers >100.5 F for 2 weeks without evidence of infection   d. Drenching night sweats without evidence of infection  2. Evidence of progressive bone marrow failure with hemoglobin <11 g/dL or platelet count <100 x 109/L  3. Massive or rapidly progressive splenomegaly (>6 cm below left costal margin)  4. Massive (>10 cm) or rapidly progressive lymphadenopathy","url":null,"context":"CTEP"},{"name":"CRF Text2","type":"Alternate Question Text","description":"Progressive disease with any one of the following characteristics ","url":null,"context":"CTEP"},{"name":"CRF Text3","type":"Alternate Question Text","description":"Progressive disease with any one of the following characteristics based on standard criteria for treatment as defined by the NCI-WG 1996 (Cheson, 1996 and Hallek, 2008).\r\n\t1. Symptomatic CLL characterized by any one of the following:\r\n\t\ta. Weight loss >=10% within the previous 6 months\r\n\t\tb. Extreme fatigue attributed to CLL\r\n\t\tc. Fevers >100.5°F for 2 weeks without evidence of infection\r\n\t\td. Drenching night sweats without evidence of infection\r\n\t2. Evidence of progressive bone marrow failure with hemoglobin <11 g/dL or platelet count <100 x 109/L\r\n\t3. Massive or rapidly progressive splenomegaly (>6 cm below left costal margin)\r\n\t4. Massive (>10 cm) or rapidly progressive lymphadenopathy\r\n","url":null,"context":"CTEP"},{"name":"Spelled out symbols for CRF text 3","type":"Alternate Question Text","description":"Progressive disease with any one of the following characteristics based on standard criteria for treatment as defined by the NCI-WG 1996 (Cheson, 1996 and Hallek, 2008).\r\n\t1. Symptomatic CLL characterized by any one of the following:\r\n\t\ta. Weight loss greater than or equal to 10 Percent within the previous 6 months\r\n\t\tb. Extreme fatigue attributed to CLL\r\n\t\tc. Fevers greater than 100.5 Degree F for 2 weeks without evidence of infection\r\n\t\td. Drenching night sweats without evidence of infection\r\n\t2. Evidence of progressive bone marrow failure with hemoglobin less than 11 g/dL or platelet count less than 100 x 109/L\r\n\t3. Massive or rapidly progressive splenomegaly (greater than 6 cm below left costal margin)\r\n\t4. Massive (greater than 10 cm) or rapidly progressive lymphadenopathy\r\n","url":null,"context":"NCIP"},{"name":"Spelled out symbols for Progressive Disease","type":"Alternate Question Text","description":"Progressive disease with any one of the following characteristics based on standard criteria for treatment as defined by the NCI-WG 1996 (Cheson, 1996 and Hallek, 2008).  1. Symptomatic CLL characterized by any one of the following:   a. Weight loss less than or equal to 10 Percent within the previous 6 months   b. Extreme fatigue attributed to CLL   c. Fevers greater than 100.5 F for 2 weeks without evidence of infection   d. Drenching night sweats without evidence of infection  2. Evidence of progressive bone marrow failure with hemoglobin less than 11 g/dL or platelet count less than 100 x 109/L  3. Massive or rapidly progressive splenomegaly (greater than 6 cm below left costal margin)  4. Massive (greater than 10 cm) or rapidly progressive lymphadenopathy","url":null,"context":"NCIP"},{"name":"COG CRF Text 01","type":"Alternate Question Text","description":"If Yes, did the patient have progression subsequent to initial 2 cycles of induction chemotherapy consisting of cyclophosphamide and topotecan?","url":null,"context":"COG"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Is the patient currently demonstrating progressive disease refractory to continuous ADT or Orchiectomy for surgical ADT?","url":null,"context":"Alliance"},{"name":"Alliance - 2","type":"Alternate Question Text","description":"Has Patient demonstrated progression of disease on palbociclib monotherapy (Arm 1) per RECIST version 1.1 criteria?","url":null,"context":"Alliance"}],"origin":"NCCTG CRF:North Central Cancer Treatment Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A275CA77-47A3-E2C8-E040-BB89AD434F94","latestVersionIndicator":"Yes","beginDate":"2011-05-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-05-04","modifiedBy":"ZHWENDY","dateModified":"2022-09-13","changeDescription":"Replaced VD Eligibility Ind-2 2018257v1 with VD ID#3506068 - Yes No Indicator - dbw\r\n03-09-2018 added spelled out symbols in alt question Text DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}